



Updating estimates of the Number of UK Stroke Patients Eligible for Endovascular Thrombectomy: Incorporating Recent Evidence to Facilitate Service Planning

Journal:	<i>European Stroke Journal</i>
Manuscript ID	ESO-21-0188.R1
Manuscript Type:	Original Research Article
Date Submitted by the Author:	14-Oct-2021
Complete List of Authors:	McMeekin, Peter; Northumbria University, School of Health, Community and Education Studies Flynn, Darren; Teesside University James, Martin; Royal Devon and Exeter Hospital, Stroke Unit Price, Christopher; Newcastle University, Institute of Neuroscience (Stroke Research Group) Ford, Gary; Oxford Academic Health Science Network White, Phil; Newcastle University, Institute of Neuroscience (Stroke Research Group)
Keywords:	Thrombectomy, Ischemic stroke, Advanced imaging, Service planning, Eligibility
Abstract:	<p>Introduction: Endovascular thrombectomy (EVT) is a highly effective treatment for acute ischemic stroke due to large arterial occlusion (LAO). To support decisions about service provision, we previously estimated the annual UK population eligible for EVT as ~10% of stroke admissions. Since then, several trials have produced evidence that could alter these figures. We update our estimates considering information from studies and trials reporting 2018-2021 on incidence, presentation time and stroke severity and consider the possible impact of predicted demographic changes in the next 10-20 years.</p> <p>Patients and Methods: We produce an updated decision-tree describing the EVT eligible population for UK stroke admissions. One-way sensitivity analyses (using upper and lower confidence intervals for estimates at each branch of our decision tree) were used to identify where further research evidence is necessary to increase certainty around estimates for numbers of EVT eligible patients.</p> <p>Results: The updated estimate for the number of UK stroke patients eligible for EVT annually was between 10,020 (no advanced imaging in early presenting patients) and 9,580 (advanced imaging in all early presenting patients), which compared with our estimates in 2017 is a minimal reduction. One-way sensitivity analyses established that enhanced evidence about eligibility for milder strokes, ASPECTS scores and pre-stroke disability are offset by evidence regarding a lower incidence of LAO. Importantly, predicted increases in life expectancy by 2040 may increase thrombectomy need by 40%.</p> <p>Discussion: Information from additional randomised trials published 2018-2020 with updated estimates of LAO prevalence had a minimal impact on overall estimates of stroke patients eligible for EVT in the UK. Ongoing research into the benefits of EVT for patients with mild stroke or</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

	<p>lower ASPECTS scores has the potential to increase the estimates of the eligible population; future need for EVT will increase with the ageing population.</p> <p>Conclusion: Our updated analyses show overall numbers eligible little changed but evidence from ongoing trials and demographic changes have the potential to increase the need for EVT significantly.</p>



1
2
3 1. Conflicting interests

4 PW was co-PI for 2 randomised trials (PISTE & STABILISE) investigating different
5 aspects of thrombectomy in acute stroke. Start-up phase of PISTE was mainly funded
6 by Stroke Association but was also part funded by unrestricted institutional
7 educational grants from Covidien & Codman who both manufacture devices used for
8 stroke thrombectomy. STABILISE was part funded by Microvention. PW has also
9 undertaken educational consultancy work within last 3 years for Microvention who
10 manufacture devices used for stroke thrombectomy. He holds institutional unrestricted
11 educational grants for a reperfusion masterclass from Stryker, Penumbra and
12 Medtronic.
13
14
15
16
17
18
19

20
21 GAF was co-PI for STABILISE and was chair of the PISTE Trial Steering
22 Committee, both trials involving thrombectomy devices. GAF has received personal
23 remuneration for educational and advisory work from Medtronic and Stryker.
24
25
26
27

28 MAJ has received personal fees and non-financial support from Boehringer
29 Ingelheim, Bayer, Bristol-Myers-Squibb and Daiichi-Sankyo outside the submitted
30 work.
31
32
33
34

35 2. Funding

36 This article presents independent research funded by the National Institute for Health
37 Research (NIHR) (NIHR201692). MAJ is supported by the NIHR ARC South West
38 Peninsula. CIP is supported by the NIHR ARC North East North Cumbria
39
40
41
42

43 3. Informed consent

44 Not Applicable
45
46
47

48 4. Ethical approval (section 2.7)

49 Not Applicable
50
51
52
53

54 5. Guarantor

55 PMc
56
57

58 6. Contributorship

59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

1
2
3 GF, PW, DF, MJ and PM researched literature and conceived the study. CP & DF were
4 involved in analysis and interpretation. PM and PW wrote the first draft of the manuscript
5 and all authors reviewed and edited the manuscript and approved the final version of the
6 manuscript.
7
8
9

10 7. Acknowledgements

11 None
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

1
2
3
4
5
6
7
8
9

Updating estimates of the Number of UK Stroke Patients Eligible for Endovascular Thrombectomy: Incorporating Recent Evidence to Facilitate Service Planning

10
11
12
13
14
15
16
17
18

McMeekin Peter, PhD; Flynn Darren, PhD; James Martin, MD; Price Christopher I, MD; Ford Gary
A, MB BChir, White Philip, MD;

19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38

Faculty of Health and Life Sciences, Northumbria University, UK (PM); School of Health and Life
Sciences, Teesside University, UK (DF); Stroke Research Group, Faculty of Medical Sciences,
Newcastle University, Newcastle Upon Tyne, UK and Newcastle upon Tyne Hospitals NHS
Foundation Trust (PW); Stroke Research Group, Faculty of Medical Sciences, , Newcastle
University, Newcastle Upon Tyne, UK and Northumbria Healthcare NHS Foundation Trust
(CP); Oxford University Hospitals NHS Foundation Trust and Oxford University, UK (GAF);
NIHR South West Peninsula Applied Research Collaboration (PenARC), Exeter, UK (MJ).

39
40
41
42
43
44
45
46
47
48
49

Correspondence to Peter McMeekin, Faculty of Health and Life Sciences, Northumbria University,
Newcastle upon Tyne, NE7 7AX, UK. Tel +44 (0)191 2156368; Fax: +44 (0)191 2156083; E-
mail: peter.mcmeekin@northumbria.ac.uk

50
51
52
53
54
55

Keywords: thrombectomy; ischemic stroke; advanced imaging; service planning

56
57
58
59
60

Word count = 2,820

INTRODUCTION

Clinical trials show that endovascular thrombectomy (EVT) is an effective treatment for acute ischemic stroke causing large artery occlusion (LAO) with or without intravenous alteplase^{1,2,3,4,5,6,7,8,9,10,11}. In 2016, the Highly Effective Reperfusion Evaluated in Multiple Endovascular Stroke trials (HERMES) individual patient meta-analysis found that for every three patients treated with EVT, one would have reduced disability by at least 1 level on the modified Rankin Scale (mRS)¹². EVT presents major challenges in many health care systems, as it is typically carried out by neurointerventionists with anaesthetic and other specialist staff support. It requires substantial imaging infrastructure: rapidly performing Computed Tomography Angiography (CTA), with or without advanced imaging by Perfusion-Computed Tomography (CTP), Magnetic Resonance imaging techniques (MR) or multiphase CTA Collateral Scoring (mCTA-CS) in a centralised model of hyperacute stroke care. Therefore, significant planning and investment is needed in most health care systems to establish capacity to deliver EVT to those stroke patients most likely to benefit.

In 2017 we previously estimated the UK eligible population for EVT to estimate demand and inform service reconfiguration and estimate the annual demand for EVT in the UK, regardless of geographic or service constraints such as non-existent care pathways or a lack of imaging and EVT facilities¹³. Subsequent studies and trials (DAWN, DEFUSE 3 and Manceau et al^{9,10,11}) have added to the evidence base about patients who could benefit from EVT. Because of the number of ongoing trials^{14,15,16,17,18} into the effectiveness of EVT in other patient subgroups, many of which have been delayed by the COVID-19 pandemic, we re-examined our previous decision-tree to produce an updated estimate of the proportion of all stroke patients eligible for EVT. We sought to quantify uncertainty around key nodes in the decision-tree to enable planners to determine the effects of any new information on estimates of the eligible population on prevalence and effectiveness of EVT in sub-populations. Furthermore, we considered future stroke populations in terms of numbers and age profile in our sensitivity analyses looking 10-20 years ahead.

PATIENTS AND METHODS

We reviewed estimates from our previous study based on national registry data from the prospective Sentinel Stroke National Audit Programme (SSNAP) for England, Wales and Northern Ireland¹⁹ and adjusted for Scotland using data from the Scottish Stroke Care Audit (SSCA)¹² and produced an updated estimate of the number of UK patients hospitalised annually with acute stroke¹⁵. The tree

1
2 estimated eligibility by evidencing exclusions at progressive stages of the typical acute care
3 pathway beginning with imaging to determine stroke type (ischaemic) followed by severity
4 (National Institutes of Health Stroke Scale score; NIHSS) and time related eligibility for treatment.
5 The tree then splits into early presenters and late presenters, with early presentation defined as
6 within the IVT license criteria. Eligibility in late presenters is determined using advanced imaging
7 as well as clinical criteria. In addition to clinical and CT imaging criteria, we also allowed for the
8 possibility of advanced imaging for early presenters for the purpose of excluding those without
9 salvageable brain tissue. We reviewed evidence at each point in our previously published decision
10 tree, updating its structure and numbers, as necessary, by expert consensus.
11
12
13
14
15
16
17
18

19 One-way sensitivity analyses (using plausible intervals for our estimates at each decision point
20 (node) of the decision tree) were performed to identify branches of the tree that would benefit from
21 additional evidence to increase certainty around the estimates for overall eligibility. The outputs
22 from these analyses are presented graphically in a tornado diagram showing the impact of numbers
23 eligible for EVT as a function of the upper and lower prediction intervals for each node of the tree.
24 The decision tree was created in Excel and is provided as supplementary material.
25
26
27
28
29
30

31 RESULTS

32 *Review of new evidence and change to nodal decision points*

33 The updated decision tree is presented in Figure 1. In a 2019 review into the epidemiology, natural
34 history and clinical presentation of large artery stroke published in 2019, Rennert and colleagues
35 estimated that the hospital incidence ranged between 28% and 40%²⁸. Therefore, the mean
36 incidence they reported, 35%, was used in our updated tree. This is lower than the previous
37 estimate (40%) based on the earlier STOP-Stroke study²¹ and the more selective HERMES trial
38 meta-analysis¹². The effect of this change was to lower the estimated eligible population, at node B
39 from 33,240 to 29,080.
40
41
42
43
44
45
46
47

48 We previously estimated that (at node G), amongst early presenting (within the IVT licence
49 window) moderate to severe strokes, 34% would be excluded from EVT because of clinical and/or
50 imaging exclusions (originally a pre-stroke modified Rankin score (mRS) of three or more, or an
51 Alberta Stroke Program Early CT Score (ASPECTS) of five or less. Proportions of patients with an
52 ASPECTS 0-5 score was based on the Interventional Management of Stroke (IMS)-3 trial CTA
53 positive subgroup²². Proportions of patients with an mRS score of three or more came from the
54 STOP-Stroke study²¹ that identified 8.7% of LAO stroke patients with a pre-stroke mRS of 3 or
55 more, which is consistent with reports from the study logs of trials included in HERMES¹².
56
57
58
59
60

1
2 However, we update our estimates of those excluded by pre-stroke dependence to include some
3 patients with a mRS of 3 because SSNAP data indicate EVT being performed on this subgroup.
4 We base the percentage on the number of patients in the SSNAP national dataset treated with IVT
5 who had a pre-stroke mRS of 3 with moderate or severe strokes ($\text{NIHSS} \geq 6$). These patients make
6 up 0.3% of all stroke patients, or 267 patients, which represents 3% of patients at node G (early
7 presenters)²³. Evidence from DEFUSE-3¹⁰ and the HERMES collaboration demonstrated the
8 benefit of EVT in patients with a CT ASPECTS score of five or more. Accordingly, we reduced
9 our estimates of patients excluded at node G by 5% (3% plus 5% less 3% to allow for a known
10 overlap between ASPECTS and pre-stroke mRS) from 34% to 24%, increasing the proportion
11 eligible in this group. Amongst later presenters (4.5hr – 12hr), it is likely that a small number of
12 patients with a pre-stroke mRS of 3 with an ASPECTS of 5 or better would be considered eligible.
13 We therefore reduced, by consensus, the clinical and imaging exclusions from 75% to 72.5%. This
14 results in an extra 210 late presenting patients progressing (to advanced imaging) from node K.
15
16
17
18
19
20
21
22
23
24
25

26 Amongst the group of EVT eligible early presenting patients we had previously estimated a 5%
27 spontaneous recanalization rate (node J). Recent evidence suggests that this rate was an
28 underestimate, and that 8.75% is a more accurate estimate²⁴. This reduces the eligible population
29 in the early-presenting group, whether advanced imaging is utilised. In the late-presenting group
30 where IVT will not be administered, the 2% spontaneous recanalisation rate observed in
31 DAWN/DEFUSE-3 trials.
32
33
34
35
36
37

38 The final piece of new evidence incorporated into our decision tree concerned patients presenting
39 between 12 and 24 hours and whose eligibility must be determined by advanced imaging. Evidence
40 from DAWN would mean that an additional 5% of patients with a moderate to severe stroke would
41 be eligible for EVT before any spontaneous recanalisation was accounted for in this late presenting
42 group⁹. Amongst DAWN participants 11.5% of patients had a moderate to severe stroke and
43 overall, 5% were found eligible for EVT after advanced imaging⁹. No evidence about those
44 presenting between 12 and 16 hours was incorporated into our tree from DEFUSE-3 because no
45 data on that specific time-period were reported and the broader eligibility criteria of ESCAPE²⁵
46 were already incorporated in our decision tree for the group presenting at 6-12h.
47
48
49
50
51
52
53
54

55 Given the complex nature of acute stroke services, to effectively plan for services estimates of
56 future eligibility for EVT are required. Like the rest of Europeans, people in the UK are living
57 longer and this trend will continue over the next two decades. The Office of National statistics
58 estimate that there will be 9.9 million 75-year-olds in 2039, an increase from 5.8 million in 2019²⁶.
59
60

1
2 Estimates of future UK stroke incidence were reported by King et al ²⁷ who used a Delphi-style
3 approach, following a review of the literature, involving experts who were aware of evidence and
4 trends in stroke epidemiology. The most common estimates for increased incidence each age group
5 was chosen along with the mean assumed current incidence. These estimates assume no change in
6 the implementation and effectiveness of the stroke prevention management of risk factors such as
7 atrial fibrillation and hypertension.
8
9
10
11
12
13

14 ***Re-estimated annual stroke patients eligible for EVT***

15
16
17 The updated decision tree is presented in Figure 1. The updated estimate of annual UK stroke
18 admissions eligible for EVT is 9,580 to 10,020. The range is described by the use, or not, of
19 advanced imaging in early presenters: 8,690 early presenters (with no use of advanced imaging)
20 plus 1,330 late presenters totalling 10,020. Or 8,250 early presenters (with 100% use of advanced
21 imaging) plus 1,330 late presenters totalling 9,580. This is overall a minimal reduction compared
22 with our previous estimates in 2017 of between 10,440 (advanced imaging used in all early
23 presenters) and 10,920 (no advanced imaging in early presenters).
24
25
26
27
28
29
30
31
32

33 ***Impact of demographic trends on estimates of eligibility and impact of uncertainty around key 34 parameters***

35
36
37
38 The tornado diagram (Figure 2) revealed the key nodes in the decision tree that are expected to have
39 the biggest impact on plans for services. They were estimated assuming that advanced imaging is
40 not used in early presenting patients. Node B, the proportion of LAOs in the stroke population,
41 either increases or decreases the annual eligible population by 1,400 patients if the proportion is
42 increased to 40% or decreased to 30% from its assumed value of 35%. If EVT is found effective in
43 milder stroke (NIHSS ≤ 5) this would increase the numbers eligible. Without an estimate of NIHSS
44 severity of when EVT would be considered effective, we considered two scenarios. The first when
45 85% (an additional 5%) of early presenting LAO patients would be treated with an NIHSS of 5 or
46 lower. The second when 95% (an additional 10%) of early presenting LAO patients would be
47 treated with an NIHSS of 5 or lower. In these circumstances the eligible population increased by
48 670 and 1,980. For later presenting patients, similar reduced exclusions by 5% and 10% to 70% and
49 65% due to NIHSS score (compared to the originally estimated 75%) would increase numbers by
50 230 and 460 patients, respectively. Furthermore, amongst the group of early presenting patients
51
52
53
54
55
56
57
58
59
60

1
2 whose NIHSS is five or lower are those who deteriorate within 24 hours. Coutts et al found that
3 progression or recurrence occurred in 7% of patients presenting with NIHSS of less than four or a
4 transient ischaemic attack²⁸. Our numbers could therefore be inflated to a small extent if it were
5 found that reperfusion is indicated for these patients.
6
7
8
9

10 Similarly, if EVT was shown to be effective in patients with ASPECT scores of 4 or less, or in
11 patients with a pre-stroke disability (mRs >2), the eligible population would also increase. At Node
12 G, if the exclusion rate dropped to 25% (from 29%) an additional 490 early presenting patients
13 would become eligible. If the exclusion rate dropped to 15% a further 1,700 early presenting
14 patients would become eligible. For later presenters, effectiveness of treatment with an ASPECT
15 score of 4 or less would increase the eligible population by 119 if exclusion at Node K dropped
16 from 75% to 70%. If exclusion at node K dropped to 65%, then a further 350 late presenting
17 patients would become eligible.
18
19
20
21
22
23
24
25

26 By 2030 and 2040, these EVT eligibility estimates could increase considerably as the UK
27 population ages.—These analyses (see Table 1) indicate that by 2030 there would be an additional
28 24,000 patients entering our tree and an additional 49,000 by 2040. Before any account is taken of
29 evidence of EVT effectiveness in new sub populations of LAO stroke, this represents approximately
30 an additional 2,400 to 4,900 LAO patients per annum eligible for thrombectomy.
31
32
33
34
35

36 DISCUSSION

37
38 Our updated analysis of the impact of new evidence between 2018-2021 on the numbers of patients
39 in the UK eligible for EVT has shown that the addition of evidence from DAWN and DEFUSE 3
40 resulted in a negligible impact on previous estimates of UK patients who are eligible for EVT. Both
41 trials increased the estimates of numbers of patients eligible in absolute terms only very modestly,
42 mainly because of their strict eligibility criteria and because we had previously allowed for EVT
43 eligibility up to 12h after onset (whether precise onset time known or not). The shift of ASPECTS
44 exclusion from <6 to <5 increased numbers eligible by a more substantial 5%. The inclusion of
45 early presenting patients with moderate or severe strokes and a pre-stroke mRS of 3 or more
46 increased annual eligibility as 3% fewer patients were deemed ineligible by this criterion.
47 However, both increases were more than offset by a modest reduction in the assumed incidence of
48 LAO (from 40 to 35%) due to new evidence²⁹ and a revision upwards in the proportion of early
49 presenters with recanalisation before EVT could be performed (from 5 to 8.75%). In the UK,
50 imaging practices may affect the observed LAO rate and the previous UK estimate of 39% may
51 reflect a smaller denominator of patients⁷.
52
53
54
55
56
57
58
59
60

1
2
3
4
5 TESLA¹⁴, TENSION¹⁵, MOSTE¹⁸, SELECT 2¹⁶, LASTE¹⁷ ENDOLOW³⁰ are amongst the
6 ongoing trials whose results could appreciably alter our estimates form eligibility.. These trials
7 have been taking place during the global COVID19 pandemic and completion and reporting of their
8 results are likely to be delayed, potentially by up to 2 years, an additional justification to updating
9 our 2017 eligibility estimates. TESLA, estimated to complete at very earliest in late 2022, will
10 consider patients with ASPECTS scores of 2-5 presenting within 24 hours of onset. It therefore has
11 the possibility to impact node G of our decision-tree (Clinical and CT exclusions in early
12 presenters) and eligibility in late presenters identified by advanced Imaging (nodes H and M).
13 Based on plausible ranges, such as the percentage of late presenters who had a pre-stroke mRS of
14 three and would have favourable CTs, this indicates differences in eligibility of several hundred
15 patients per year in the late-presenting group. TENSION, now estimated to complete, at very
16 earliest, in March 2024 includes patients with an ASPECTS score of 3-5 presenting within 11 hours
17 and includes patients with low NIHSS scores as does ENDO-LOW trial. These trials have the
18 possibility to impact our estimates at nodes C, G and H. Eligibility for EVT in patients with mild
19 strokes (NIHSS <6) has the potential to considerably increase the eligible population by 5,820 at
20 node D. Assuming that this group of patients were equally likely to present early (78%) and
21 because lower NIHSS scores are likely to be associated with higher ASPECTS scores and mRS <3,
22 the proportion of early presenters excluded at node G would decrease appreciably. However, it is
23 probable that most of the low NIHSS early presenters would be lower (SSNAP reports 50% patients
24 with mild strokes presenting within 270 minutes therefore of 5,820, 2,910 would still be eligible at
25 point J). Recent evidence also suggests benefits in patients with a pre-existing mRS of 3 (and
26 above) further reducing clinical exclusions. Larsson and colleagues observed that 20% of patients
27 with pre-stroke disability receiving EVT returned to their pre-stroke functional level³¹.
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

47 SELECT 2, estimated to report at very earliest in early 2022, includes patients with an ASPECTS
48 score of 3 or above within 24 hours of “last known well” and therefore has a similar potential to
49 impact our estimates as TESLA (nodes G, H and M). LASTE, reporting at very earliest February
50 2022, includes early presenters with an ASPECTS score of 0-5, or 4-5 if aged 80 or over. The
51 impact of LASTE is therefore at node G and node H.
52
53
54
55
56

57 Perhaps the most significant factor to service planners though is the effect of an ageing population,
58 which suggests numbers of stroke patients eligible for EVT increasing by >20% in 2030 and >40%
59 in 2040. Ageing may be associated with poorer pre-stroke health but as there have been few
60

1
2 participants aged 85+ in stroke EVT trials, the precise incidence of treatable LAO is unclear in this
3 population. We also know that aging populations are increasing more in rural areas (generally living
4 further away from urban EVT centres), resulting in later presentation on average.
5
6
7

8
9 Our estimates take no account of cost effectiveness, which may influence decisions about eligibility
10 for some groups with pre-existing disability or where EVT may reduce mortality in patients who
11 survive with significant disability.
12
13
14

15 **CONCLUSION**

16
17 The addition of new trial evidence from 2017-2021 has not substantially altered our previous
18 estimate of stroke patients in the UK that are eligible for EVT each year. Although ongoing trials
19 have the prospect of further considerably revising estimates of overall eligibility (mostly increasing
20 them), the Covid19 pandemic has delayed most of these trials appreciably and so our updated
21 estimates and associated estimates of uncertainty are therefore an important source of information
22 for those managing or commissioning EVT services in the next 2-3 years. Over a longer time
23 horizon, population demographic trends appear to have the greatest impact on the incidence of LAO
24 stroke and consequent demand for EVT services.
25
26
27
28
29
30
31
32

33 **Figure Legends**

34
35 Figure 1: Eligible Population (a; Total UK population including those deemed to be geographically
36 inaccessible. b: Confirmed infarcts, excluding ~2% of patients whose status is unconfirmed.
37 Besides cerebral infarcts most acute subdural haematomas would also not be entered in to SSNAP
38 nor SSCA. c: Includes basilar artery occlusions eligible for treatment if presenting within 12 hours.
39 Others are assumed eligible unless they meet any subsequent exclusion. d: "Early presenters"- those
40 presenting within licensed IVT window), late presenters or SUTO (4.5-12h or last known well up to
41 12h ago) Note: Patients within the large lower grey shaded box are all dealt with by advanced
42 imaging (8,250 + 1,330) those who are early presenters (8,250 on the left-hand side) can bypass that
43 step.
44
45
46
47
48
49

50
51 Figure 2: Tornado diagram of one-way sensitivity analyses for key decision nodes
52
53
54
55
56
57
58
59
60

REFERENCES

- 1 Berkhemer OA, Puck SS, Fransen PS, Beumer D, van den Berg LD, Lingsma HF, et al. A randomized trial of intraarterial treatment for acute ischemic stroke. *N Engl J Med.* 2015; 372: 11–20
- 2 Campbell BC, Mitchell PJ, Kleinig TJ, Dewey HM, Churilov L, Yassi N, et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. *N Engl J Med.* 2015; 372: 1009–1018
- 3 Goyal M, Demchuk AM, Menon BK, Eesa M, Rempel JL, Thornton J, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. *N Engl J Med.* 2015; 372: 1019–1030
- 4 Saver JL, Goyal M, Bonafe A, Diener H-C, Levy EI, Pereira VM, et al. Stent-retriever thrombectomy after intravenous t-PA vs t-PA alone in stroke. *N Engl J Med.* 2015; 372: 2285–2295
- 5 Jovin TG, Chamorro A, Cobo E, de Miquel MA, Molina CA, Rovira A, et al. Thrombectomy within 8 hours after symptom onset in ischemic stroke. *N Engl J Med.* 2015; 372: 2296–2306
- 6 Bracard S, Ducrocq X, Mas JL, Soudant M, Openheim C, Moulin T, et al. Mechanical thrombectomy after intravenous alteplase versus alteplase alone after stroke (THRACE): a randomised controlled trial. *Lancet Neurol* 2016; 15 (11): 1138–1147
- 7 Muir KW, Ford GA, Messow CM, Ford I, Murray A, Clifton A, et al. Endovascular therapy for acute ischemic stroke: the Pragmatic Ischaemic Stroke Thrombectomy Evaluation (PISTE) randomised, controlled trial. *J Neurol Neurosurg Psychiatry.* 2016; 0:1–7.
- 8 Mocco J, Zaidat OO, von Kummer R, Yoo AJ, Gupta R, Lopes D, et al. Aspiration Thrombectomy After Intravenous Alteplase Versus Intravenous Alteplase Alone. *Stroke.* 2016; 47:2331-2338,
- 9 Nogueira RG, Jadhav AP, Haussen DC, Bonafe A, et al. Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct. *The New England Journal of Medicine.* 2018. 378(1):11-21.
- 10 Albers GW, Marks MP, Kemp S, Christensen S et al, Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging. *The New England Journal of Medicine.* 2018; 378:708-718 DOI: 10.1056/NEJMoa1713973
- 11 Manceau, P-F, Soize, S, Gawlitzka, M., Fabre, Get al. Is there a benefit of mechanical thrombectomy in patients with large stroke (DWI -ASPECTS \leq 5)? (2018). *Eur J Neurol*, 25: 105-110. doi:10.1111/ene.13460
- 12 Goyal M, Menon BK, van Zwam WH, Dippel DWJ, Mitchell PJ, Demchuk AM, et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. *The Lancet.* 2016; 387(10029):1723 – 1731
- 13 McMeekin P, White P, Martin J, Price C, et al, Estimating the number of UK stroke patients eligible for endovascular thrombectomy, 2017 *European Stroke Journal*, vol. 2, no. 4, pp. 319-326. <https://doi.org/10.1177/2396987317733343>
- 14 ClinicalTrials.gov. National Library of Medicine (US). Identifier NCT00287391, The TESLA Trial: Thrombectomy for Emergent Salvage of Large Anterior Circulation Ischemic Stroke (TESLA), [accessed 14 January 2021]; <https://clinicaltrials.gov/ct2/show/NCT03805308>
- 15 ClinicalTrials.gov. National Library of Medicine (US). Identifier NCT03094715, Efficacy and Safety of Thrombectomy in Stroke With Extended Lesion and Extended Time Window (Tension), [accessed 14 January 2021]; <https://clinicaltrials.gov/ct2/show/NCT03094715>
- 16 ClinicalTrials.gov. National Library of Medicine (US). Identifier NCT03876457, SELECT 2: A Randomized Controlled Trial to Optimize Patient's Selection for Endovascular Treatment in Acute Ischemic Stroke (SELECT2), [accessed 14 January 2021]; <https://clinicaltrials.gov/ct2/show/NCT03876457>

- 1
2 17 ClinicalTrials.gov. National Library of Medicine (US). Identifier NCT03876457, Large Stroke
3 Therapy Evaluation (LASTE), [accessed 14 January 021];
4 <https://clinicaltrials.gov/ct2/show/NCT03811769>
5
6 18 ClinicalTrials.gov. National Library of Medicine (US). Identifier NCT03876457, Minor Stroke
7 Therapy Evaluation (MOSTE), [accessed 14 January 021];
8 <https://clinicaltrials.gov/ct2/show/NCT03796468>
9
10 19 Royal College of Physicians. Sentinel Stroke National Audit Programme (SSNAP): Summary
11 Report October/ December 2015. [https://www.strokeaudit.org/results/Clinical-audit/National-](https://www.strokeaudit.org/results/Clinical-audit/National-Results.aspx)
12 [Results.aspx](https://www.strokeaudit.org/results/Clinical-audit/National-Results.aspx) (Accessed 23 October 2016)
13
14 20 NHS National Service Scotland. Scottish Stroke Improvement Programme 2016 Report.
15 [http://www.strokeaudit.scot.nhs.uk/Publications/docs/Scottish-Stroke-Improvement-Programme-](http://www.strokeaudit.scot.nhs.uk/Publications/docs/Scottish-Stroke-Improvement-Programme-report-2016.pdf?)
16 [report-2016.pdf?](http://www.strokeaudit.scot.nhs.uk/Publications/docs/Scottish-Stroke-Improvement-Programme-report-2016.pdf?) (Accessed 23 October 2016)
17 21 Smith WS, Lev MH, English JD, Camargo EC, Chou M, Gonzalez G, et al. Significance of large vessel intracranial occlusion causing acute
18 ischemic stroke and TIA. *Stroke*. 2009; 40:3834–3840.
19
20 22 Hill MD, Demchuk AM, Goyal M, Jovin TG, Foster LD, Tomsick TA, et al. Alberta Stroke
21 Program early computed tomography score to select patients for endovascular treatment:
22 Interventional Management of Stroke (IMS)-III Trial. *Stroke*. 2014; 45:444–449
23
24 23 Allen, M., James, C., Frost, J., Liabo, K et al (2021) Stroke Audit Machine Learning (SAMueL):
25 Use of simulation and machine learning to identify key levers for maximising the disability
26 benefit of intravenous thrombolysis in acute stroke pathways. (2021) Available online at:
27 <https://samuel-book.github.io/samuel-1/>. DOI: 10.5281/zenodo.5078131
28
29 24 Flores A, Ustrell X, Seró L, Pellisé A, Rodriguez P, Viñas J, et al. Vascular Occlusion Evolution
30 in Endovascular Reperfusion Candidates Transferred from Primary to Comprehensive Stroke
31 Centers. *Cerebrovasc Dis* 2020;49(5):550-555
32
33 25 Goyal M, Demchuk AM, Menon BK, Eesa M, et al. Randomized assessment of rapid
34 endovascular treatment of ischemic stroke. *N Engl J Med*. 2015 Mar 12;372(11):1019-30. doi:
35 10.1056/NEJMoa1414905. Epub 2015 Feb 11. PMID: 25671798.
36
37 26 ONS (2018) Population changes by age National population projections - Office for National
38 Statistics (Accessed 23 February 2021)
39
40 27 King D, Wittenberg R, Patel A, Quayyum Z, et al. The future incidence, prevalence and costs of
41 stroke in the UK. *Age Ageing*. 2020 Feb 27;49(2):277-282. doi: 10.1093/ageing/afz163. PMID:
42 31957781; PMCID: PMC7047821.
43
44 28 Coutts SB, Modi J, Patel SK, Demchuk AM, Goyal M, Hill MD; Calgary Stroke Program.
45 CT/CT angiography and MRI findings predict recurrent stroke after transient ischemic attack and
46 minor stroke: results of the prospective CATCH study. *Stroke*. 2012 Apr;43(4):1013-7.
47
48 29 Rennert RC, Wali AR, Steinberg JA, Santiago-Dieppa DR, et al. Epidemiology, Natural History,
49 and Clinical Presentation of Large Vessel Ischemic Stroke. *Neurosurgery*. 2019 Jul
50 1;85(suppl_1):S4-S8. doi: 10.1093/neuros/nyz042. PMID: 31197329; PMCID: PMC6584910.
51
52 30 ClinicalTrials.gov. National Library of Medicine (US). Identifier NCT04167527, Endovascular
53 Therapy for Low NIHSS Ischemic Strokes (ENDOLOW), [accessed 14 January 021];
54 <https://clinicaltrials.gov/ct2/show/NCT04167527>
55
56 31 Larsson A, Karlsson C, Rentzos A, et al. Do patients with large vessel occlusion ischemic stroke
57 harboring prestroke disability benefit from thrombectomy?. *J Neurol*. 2020;267(9):2667-2674.
58 doi:10.1007/s00415-020-09882-5
59
60

Figure 1





Figure 2





Or Peer Review

Table 1. Future Estimates of population and stroke incidence


Age Band	Pop increase 2030 from 2020	Pop increase 2040 from 2020	Mean Incidence per 100,000	Increased Incidence 2030 (%)	Increased Incidence 2040 (%)	Additional Stroke numbers 2030	Additional Stroke numbers 2040
40-64	342,712	336,897	131	0	0	449	441
65-74	958,520	1,316,576	509	0	0	4879	6,701
75-84	1,096,676	2,044,190	947	0	0	10,386	18,982
85-100	442,085	1,124,513	1823	5	10.5	8,462	22,652
Total	2,839,993	4,822,176	-	-	-	24,176	48,776


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60





1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60







1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



5,820

5,120






1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

maging Pathway


Node, estiamte (range) J. S

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Node	Description	Point	Low
	Number of strokes	95500	119600
A	Iccheamic Strokes (%)	87.0%	86%
B	LAO of Ischaemic Strokes (%)	35.0%	30%
C	NIHSS >= 6	80.0%	85%
D	KTO / LSW < 12 hours	78.0%	76%
E	Percentage of KTO / LSW Unknown time of Onset	68.5%	65%
F	Percentage of < 12 presenting early	74.0%	70%
G	Clinical CT Exclusions Early Presenters	29.0%	30%
H	Clinical CT Exclusions Late Presenters	72.5%	70%
I	Advanced Imaging Exclusiouons Early Presenters	5.0%	3%
K	Advanced Imaging Exclusiouons Late Presenters	43.0%	40%
J	Spontaneous recanalisation in early presenters	8.8%	5%
L	Spontaneous recanalisation in late presenters	2.0%	1%
M	Presentations after 24hrs NIHSS > 6 LAO	11.5%	10%
N	DAWN Eligibility in 12- 24hr presenters	5.0%	4%

One Way



■ Low Esti

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


For Peer Review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

High
144300
88%
40%
95%
80%
72%
78%
20%
65%
7%
46%
10%
3%
13%
6%

For Peer

Sensitivity Anayses



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

imate ■ High Estimate

For Peer Review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review




1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




For Peer Review


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


Version 1





1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60






1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


- A Icheamic Strokes (%)
- B LAO of Ischaemic Strokes (%)
- C NIHSS ≥ 6
- D KTO / LSW < 12 hors
Percentage of KTO / LSW Unknown time of
- E Onset
- F Percentage of < 12 presenting early
- G Clinical CT Exclusions Early Presenters
- H Clinical AI Exclusions Late Presenters
- I Advanced Imaging Exclusiouons Early Presenters
- K Advanced Imaging Exclusiouons Late Presenters
- j Sponeaneous recalisation in early presenters
- L Sponeaneous recalisation in late presenters

For Peer Review



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

7,050



30

For Peer Review

1	
2	
3	
4	87.0%
5	
6	40.0%
7	
8	80.0%
9	
10	78.0%
11	
12	68.5%
13	
14	74.0%
15	34.0%
16	75.0%
17	5.0%
18	
19	43.0%
20	
21	
22	5.0%
23	2.0%
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	

For Peer Review